TREM2 Antibody
Description
Product Specs
Product Science Overview
Triggering receptor expressed on myeloid cells 2 (TREM2) is a type I transmembrane receptor belonging to the immunoglobulin superfamily. It plays a crucial role in the regulation of the immune response, particularly in myeloid cells. TREM2 is expressed on various myeloid cells, including macrophages, microglia, and dendritic cells .
TREM2 is characterized by its single immunoglobulin-like domain, a transmembrane region, and a short cytoplasmic tail. The receptor is known to bind to several ligands, including lipids and lipoproteins. Upon ligand binding, TREM2 associates with DNAX activation protein 12 (DAP12), leading to the activation of downstream signaling pathways such as the PI3K-Akt pathway and spleen tyrosine kinase (Syk) pathway . These pathways are involved in promoting cell survival, phagocytosis, and cytokine production .
TREM2 has been implicated in various diseases, including neurodegenerative disorders and cancers. In Alzheimer’s disease, TREM2 is associated with the phagocytosis of amyloid plaques and the survival of microglia. Mutations in the TREM2 gene, such as the R47H mutation, are linked to an increased risk of late-onset Alzheimer’s disease . In the context of cancer, TREM2 is expressed on tumor-associated macrophages and has been shown to play a dual role in the inflammatory response against tumors and pro-tumoral immunosuppression .
Mouse anti-human TREM2 antibodies are monoclonal antibodies developed to specifically target human TREM2. These antibodies are used in various research applications, including the study of TREM2’s role in diseases and the development of potential therapeutic strategies. By binding to human TREM2, these antibodies can help elucidate the receptor’s function and its involvement in disease processes .
Given its role in regulating the immune response, TREM2 has emerged as a potential therapeutic target. In Alzheimer’s disease, enhancing TREM2 function could promote the clearance of amyloid plaques and support microglial survival. In cancer, targeting TREM2 on tumor-associated macrophages may modulate the immune response to achieve antitumor activity .
